

1. (Amended) A sustained release oral dosage form comprising a liquid, self-emulsifying antiviral drug formulation comprising up to 60 wt% of a solubilized antiviral drug, wherein the dosage form is configured to administer a therapeutically effective dose of said antiviral drug over a period of at least 4 hours after oral administration with no more than 30% by weight of said drug formulation being released within the first 1 hour after oral administration.

3. (Amended) A sustained release oral dosage form comprising a liquid, self-emulsifying antiviral drug formulation comprising up to 60 wt% of a solubilized antiviral drug, wherein the dosage form is configured to administer a therapeutically effective dose of said antiviral drug over a period of at least 12 hours after oral administration with no more than 30% by weight of said drug formulation being released within the first 4 hours after oral administration.

4. (Amended) A sustained release oral dosage form comprising a liquid, self-emulsifying antiviral drug formulation comprising up to 60 wt% of a solubilized antiviral drug, wherein the dosage form is configured to administer a therapeutically effective dose of said antiviral drug over a period of 24 hours after oral administration with no more than 30% by weight of said drug formulation being released within the first 12 hours after oral administration.